Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nile Therapeutics Inc.

Division of Capricor Therapeutics Inc.
www.nilethera.com

Latest From Nile Therapeutics Inc.

Capricor Cardiac Stem Cell Therapy Endorsed Through Janssen Deal

Janssen inks an option agreement with California-based Capricor, making a tentative bet on the allogeneic stem cell therapy.

BioPharmaceutical North America

Deals Shaping The Medical Industry, September 2013

Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing.

BioPharmaceutical Medical Device

Small biotechs access stock market; bubble concerns rise

From initial public offerings to reverse stock splits and mergers, the public markets are the place to be for biotechnology companies as small and mid-sized firms take advantage of rising investor interest in the drug development business.

Nile buys Capricor to access cash, diversify

Publicly-traded cardiovascular drug maker Nile Therapeutics agreed to acquire the private cardiac stem cell therapy developer Capricor in a stock-for-stock, tax-free reverse merger that will give Capricor's investors 90% ownership of the combined company, which will be renamed Capricor Therapeutics.

Cardiovascular
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
  • Therapeutic Areas
  • Cardiovascular
  • Renal System
  • Alias(es)
  • SMI Products Inc.
  • Nile Pharmaceuticals Inc.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Capricor Therapeutics Inc.
  • Senior Management
  • Joshua A Kazam, Pres. & CEO
    Daron Evans , CFO
    Hsiao Dee Lieu, MD, VP, Clin. Research
    Darlene Horton, MD, CMO
  • Contact Info
  • Nile Therapeutics Inc.
    Phone: (650) 458-2670
    4 West 4th Ave.
    Ste. 94402
    San Mateo, CA 94402
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register